Division of Pulmonary, Critical Care & Sleep Medicine

Lewis J. Rubin, MD

Professor of Medicine

Pulmonary and Critical Care Division

Director, PAH Program

 

INVESTIGATIVE INTERESTS:

  1. Pulmonary Vascular Disease
  2. Pulmonary Arterial Hypertension (PAH)

INVESTIGATIVE INTERESTS:

  1. Cardiovascular Pulmonary Interrelationships
  2. Regulation and Control of Pulmonary Vasomotor Tone

SELECTED PUBLICATIONS:

    Books:
  1. Primary Pulmonary Hypertension, LJ Rubin and SR Rich, editors. 1996. Marcel Dekker, NY, NY.
  2. Pulmonary Circulation, AJ Peacock and LJ Rubin, editors, in press 2003. Edward Arnold Publishers, London, UK.
  3. Peer-Review Articles:
  4. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Tapson VF, Clayton LM, Crow JW and the PPH Study Group: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301.
  5. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, et al Rubin LJ, for the International Primary Pulmonary Hypertension Study Group: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335:609-616.
  6. Yuan XJ, Tod ML, Rubin LJ and Blaustein MP: Nitric oxide hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proceedings of the National Academy of Sciences USA 1996; 93:10489-10494.
  7. Rubin LJ: Current concepts: Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117.
  8. McCann UD, Seiden LS, R Rubin LJ, Ricaurte GA: Brain serotonin neurotoxicity and primary pulmonary hypertension: Fenfluramine (Pondimin) and dexfenfluramine (Redux). JAMA 1997; 278:666-672.
  9. Wang J, Juhaszova M, Rubin LJ and Yuan XJ: Hypoxia inhibits gene expression of voltage-gated K+ channel alpha-subunits in pulmonary artery smooth muscle cells. J Clin Invest, 1997; 100:2347-2353.
  10. Yuan XJ, Wang J, Juhaszova M, Gaine SP and Rubin LJ: Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351:726-727.
  11. Wang J, Juhaszova M, Conte JV, Gaine SP, Rubin LJ and Yuan XJ-J: Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet 1998; 352:912-914.
  12. Yuan XJ, Aldinger AM, Magdalena J, Conte JV, Wang J, Orens JB and Rubin LJ: Dysfunctional voltage-gated potassium channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98:1400-1406.
  13. Gaine S and Rubin LJ: Primary pulmonary hypertension. Lancet 1998; 352:719-725.
  14. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, et al.: Continuous Intravenous Epoprostenol for Pulmonary Hypertension due to the Scleroderma Spectrum of Disease. Ann Intern Med2000; 132: 425-434.
  15. Platoshyn O, Yu Y, Golovina VA, McDaniel SS, Krick S, Li L, Wang J-Y, Rubin LJ, Yuan JX-J Chronic hypoxia selectively inhibits Kv channel expression and function in pulmonary artery mycocytes. Am J Physiol. (Lung Cell Mol Physiol) 2001; 280:L801-812.
  16. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A, Sweeney M, Rubin LJ, Yuan JX-J. Upregulated TRP and enhanced capacitative Ca2+ entry in human pulmonary artery myocytes during proliferation. Am J. Physiol. (Heart Circ. Physiol.) 280:H746-H755, 2001.
  17. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic Thromboembolic Pulmonary Hypertension. N. Eng J Med 2001; 345:1465-1472.
  18. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainsio M, Bodin F, Rubin LJ. Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: A Randomised Placebo-Controlled Study. Lancet 2001; 358: 1119-1123.
  19. Krick S, Platoshyn O, Sweeney M, McDaniel SS, Zhang S, Rubin LJ, Yuan JX-J. Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells. Am J Physiol (Heart Circ Physiol) 2001; 282: H184-H193.
  20. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, et al: Bosentan Therapy for Pulmonary Arterial Hypertension. N Eng J Med 2002; 346: 896-903.
  21. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26: 194-201.
  22. Olschewski H, Higenbottam TW, Naeije R, Simonneau G, Galie N, Rubin LJ, Nikkho S et al: Inhaled Iloprost for Severe Pulmonary Hypertension. N Eng J Med 2002; 347:322-329.
  23. Galiè N, Hinderliter AL, Torbicki, A, Fourme T, Simonneau G, Pulido T, Espinola-Zabaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick RN, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin LJ. Effects of the Oral Endothelin-Receptor Antagonist Bosentan on Echocardiographic and Doppler Measures in Patients with Pulmonary Arterial Hypertension. J Amer Coll Cardiol 2003; 41: 1380-1386.
  24. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan J-XJ: Bone Morphogenic Proteins Induce Apoptosis in Human Pulmonary Vascular Smooth Muscle Cells. Am J Physiol Lung Cell Mol Physiol 285: L740-L754, 2003.

PubMed:

Board Certified:

  • Internal Medicine
  • Pulmonary Medicine

To make an appointment

For more information write to ljrubin@ucsd.edu